Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964447 | 0.90 | CD274 (0.39) | CD274PDCD1S1PR1S1PR3DGAT1 | |
| SCHEMBL9933707 | 0.82 | CD274 (0.38) | CD274PDCD1CYP2D6VDRS1PR1 | |
| SCHEMBL12004396 | 0.81 | CD274 (0.41) | CD274PDCD1CYP2D6VDRS1PR1 | |
| SCHEMBL13117512 | 0.81 | VDR (0.44) | CD274PDCD1VDRS1PR1S1PR3 | |
| SCHEMBL12577844 | 0.81 | CD274 (0.41) | CD274PDCD1CYP2D6VDR | |
| SCHEMBL12578213 | 0.81 | FFAR1 (0.37) | CD274PDCD1CYP2D6 | |
| SCHEMBL12577725 | 0.80 | PDCD1 (0.36) | CD274PDCD1VDRPIM1SCN9A | |
| SCHEMBL9964446 | 0.80 | CD274 (0.40) | CD274PDCD1CYP2D6VDRS1PR1 | |
| SCHEMBL12019247 | 0.79 | TDP1 (0.41) | CD274 | |
| SCHEMBL12004138 | 0.78 | CD274 (0.39) | CD274PDCD1CYP2D6VDRS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | CD274 2600/4885PDCD1 2193/4885CYP2D6 3804/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | CD274 4376/4885PDCD1 4644/4885CYP2D6 3029/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | CD274 4445/4885PDCD1 4690/4885CYP2D6 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.